175 related articles for article (PubMed ID: 33812182)
1. Involvement of small extracellular vesicle-derived TIE-1 in the chemoresistance of ovarian cancer cells.
Misawa T; Toyoshima M; Kitatani K; Ishibashi M; Hasegawa-Minato J; Shigeta S; Yaegashi N
Cancer Treat Res Commun; 2021; 27():100364. PubMed ID: 33812182
[TBL] [Abstract][Full Text] [Related]
2. Tyrosine kinase receptor TIE-1 mediates platinum resistance by promoting nucleotide excision repair in ovarian cancer.
Ishibashi M; Toyoshima M; Zhang X; Hasegawa-Minato J; Shigeta S; Usui T; Kemp CJ; Grandori C; Kitatani K; Yaegashi N
Sci Rep; 2018 Sep; 8(1):13207. PubMed ID: 30181600
[TBL] [Abstract][Full Text] [Related]
3. Checkpoint kinase 2 (Chk2) supports sensitivity to platinum-based treatment in high grade serous ovarian cancer.
Alkema NG; Tomar T; van der Zee AG; Everts M; Meersma GJ; Hollema H; de Jong S; van Vugt MA; Wisman GB
Gynecol Oncol; 2014 Jun; 133(3):591-8. PubMed ID: 24657486
[TBL] [Abstract][Full Text] [Related]
4. Expression of miR-136 is associated with the primary cisplatin resistance of human epithelial ovarian cancer.
Zhao H; Liu S; Wang G; Wu X; Ding Y; Guo G; Jiang J; Cui S
Oncol Rep; 2015 Feb; 33(2):591-8. PubMed ID: 25482209
[TBL] [Abstract][Full Text] [Related]
5. HE4 promotes collateral resistance to cisplatin and paclitaxel in ovarian cancer cells.
Ribeiro JR; Schorl C; Yano N; Romano N; Kim KK; Singh RK; Moore RG
J Ovarian Res; 2016 May; 9(1):28. PubMed ID: 27184254
[TBL] [Abstract][Full Text] [Related]
6. Selective inhibition of tumor cell associated Vacuolar-ATPase 'a2' isoform overcomes cisplatin resistance in ovarian cancer cells.
Kulshrestha A; Katara GK; Ginter J; Pamarthy S; Ibrahim SA; Jaiswal MK; Sandulescu C; Periakaruppan R; Dolan J; Gilman-Sachs A; Beaman KD
Mol Oncol; 2016 Jun; 10(6):789-805. PubMed ID: 26899534
[TBL] [Abstract][Full Text] [Related]
7. Sodium arsenite ± hyperthermia sensitizes p53-expressing human ovarian cancer cells to cisplatin by modulating platinum-DNA damage responses.
Muenyi CS; Pinhas AR; Fan TW; Brock GN; Helm CW; States JC
Toxicol Sci; 2012 May; 127(1):139-49. PubMed ID: 22331493
[TBL] [Abstract][Full Text] [Related]
8. Small extracellular vesicles ameliorate peripheral neuropathy and enhance chemotherapy of oxaliplatin on ovarian cancer.
Zhang Y; Li C; Qin Y; Cepparulo P; Millman M; Chopp M; Kemper A; Szalad A; Lu X; Wang L; Zhang ZG
J Extracell Vesicles; 2021 Mar; 10(5):e12073. PubMed ID: 33728031
[TBL] [Abstract][Full Text] [Related]
9. Therapy-induced secretion of spliceosomal components mediates pro-survival crosstalk between ovarian cancer cells.
Shender VO; Anufrieva KS; Shnaider PV; Arapidi GP; Pavlyukov MS; Ivanova OM; Malyants IK; Stepanov GA; Zhuravlev E; Ziganshin RH; Butenko IO; Bukato ON; Klimina KM; Veselovsky VA; Grigorieva TV; Malanin SY; Aleshikova OI; Slonov AV; Babaeva NA; Ashrafyan LA; Khomyakova E; Evtushenko EG; Lukina MM; Wang Z; Silantiev AS; Nushtaeva AA; Kharlampieva DD; Lazarev VN; Lashkin AI; Arzumanyan LK; Petrushanko IY; Makarov AA; Lebedeva OS; Bogomazova AN; Lagarkova MA; Govorun VM
Nat Commun; 2024 Jun; 15(1):5237. PubMed ID: 38898005
[TBL] [Abstract][Full Text] [Related]
10. Regulation of survival and chemoresistance by HSP90AA1 in ovarian cancer SKOV3 cells.
Chu SH; Liu YW; Zhang L; Liu B; Li L; Shi JZ; Li L
Mol Biol Rep; 2013 Jan; 40(1):1-6. PubMed ID: 23135731
[TBL] [Abstract][Full Text] [Related]
11. Identifying novel hypoxia-associated markers of chemoresistance in ovarian cancer.
McEvoy LM; O'Toole SA; Spillane CD; Martin CM; Gallagher MF; Stordal B; Blackshields G; Sheils O; O'Leary JJ
BMC Cancer; 2015 Jul; 15():547. PubMed ID: 26205780
[TBL] [Abstract][Full Text] [Related]
12. Circumvention of cisplatin resistance in ovarian cancer by combination of cyclosporin A and low-intensity ultrasound.
Yu T; Yang Y; Zhang J; He H; Ren X
Eur J Pharm Biopharm; 2015 Apr; 91():103-10. PubMed ID: 25668779
[TBL] [Abstract][Full Text] [Related]
13. ZEB1 Promotes Chemoresistance to Cisplatin in Ovarian Cancer Cells by Suppressing SLC3A2.
Cui Y; Qin L; Tian D; Wang T; Fan L; Zhang P; Wang Z
Chemotherapy; 2018; 63(5):262-271. PubMed ID: 30481785
[TBL] [Abstract][Full Text] [Related]
14. MircroRNA-139 sensitizes ovarian cancer cell to cisplatin-based chemotherapy through regulation of ATP7A/B.
Xiao F; Li Y; Wan Y; Xue M
Cancer Chemother Pharmacol; 2018 May; 81(5):935-947. PubMed ID: 29594361
[TBL] [Abstract][Full Text] [Related]
15. Downregulation of RIF1 Enhances Sensitivity to Platinum-Based Chemotherapy in Epithelial Ovarian Cancer (EOC) by Regulating Nucleotide Excision Repair (NER) Pathway.
Liu YB; Mei Y; Tian ZW; Long J; Luo CH; Zhou HH
Cell Physiol Biochem; 2018; 46(5):1971-1984. PubMed ID: 29719287
[TBL] [Abstract][Full Text] [Related]
16. Knockdown of Eag1 Expression by RNA Interference Increases Chemosensitivity to Cisplatin in Ovarian Cancer Cells.
Hui C; Lan Z; Yue-li L; Li-lin H; Li-lin H
Reprod Sci; 2015 Dec; 22(12):1618-26. PubMed ID: 26079730
[TBL] [Abstract][Full Text] [Related]
17. Predicting chemoresponsiveness in epithelial ovarian cancer patients using circulating small extracellular vesicle-derived plasma gelsolin.
Gerber E; Asare-Werehene M; Reunov A; Burger D; Le T; Carmona E; Mes-Masson AM; Tsang BK
J Ovarian Res; 2023 Jan; 16(1):14. PubMed ID: 36642715
[TBL] [Abstract][Full Text] [Related]
18. Leukotriene B4 receptor-2 contributes to chemoresistance of SK-OV-3 ovarian cancer cells through activation of signal transducer and activator of transcription-3-linked cascade.
Park J; Park SY; Kim JH
Biochim Biophys Acta; 2016 Feb; 1863(2):236-43. PubMed ID: 26597704
[TBL] [Abstract][Full Text] [Related]
19. The cisplatin-induced lncRNA PANDAR dictates the chemoresistance of ovarian cancer via regulating SFRS2-mediated p53 phosphorylation.
Wang H; Fang L; Jiang J; Kuang Y; Wang B; Shang X; Han P; Li Y; Liu M; Zhang Z; Li P
Cell Death Dis; 2018 Oct; 9(11):1103. PubMed ID: 30375398
[TBL] [Abstract][Full Text] [Related]
20. Let-7e Suppresses DNA Damage Repair and Sensitizes Ovarian Cancer to Cisplatin through Targeting PARP1.
Xiao M; Guo J; Xie L; Yang C; Gong L; Wang Z; Cai J
Mol Cancer Res; 2020 Mar; 18(3):436-447. PubMed ID: 31722968
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
